Table 7.
The comparison of outcomes with different therapeutic regimens.
| HQ | HQ plus AZ | FAV-containing regimen | P-value | |
|---|---|---|---|---|
| Number of cases, % | 23 (13.2) | 113 (64.9) | 32 (18.4) | |
| Diagnostic criteriaConfirmed casesRadiologically diagnosedClinically suspected | 1634 | 74318 | 2750 | <0.001 |
| Diseases severity, nMild ModerateSevere | 1553 | 158612 | 31514 | <0.001 |
| Nausea/vomitingElevation of transaminases | 11 | 53 | 510 | 0.038<0.001 |
| Median time to defervescence, days* | 1 (0–4) | 1 (0–11) | 3 (0–8) | <0.001 |
| Median time to clinical improvement on therapy*, days | 1 (1–6) | 1.5 (1–11) | 6 (1–20) | <0.001 |
| Median duration of LOS, days | 2 (1–21) | 4 (1–15) | 7.5 (2–24) | 0.001 |
* Treatment response analysis was made in 165 patients who had been discharged.